This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy

Patients pathologically confirmed with solid tumors that requires radiotherapy or surgery will be recruited to this study. Tumor samples were obtained from patients underwent surgery to establish the baseline status of biomarker assessed. Peripheral and microbiota will also be collected before and after surgery. For patients undergoing radiotherapy, tumor biopsy as well as collection of blood samples and microbiota will be performed during the course of treatment. These biological specimens will be used for assessment of tumor phenotypes and for exploration of potential biomarkers that could predict the tumor response to therapeutics and prognsis in patients with solid tumors.

Inclusion Criteria:

• Pathological proven diagnosis of solid tumors
• Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery
• Patient must provide study-specific informed consent prior to study entry

Exclusion Criteria:

• History of autoimmune diseases
• History of immunotherapy
• Prior radiation therapy that would result in overlap of planned radiation therapy fields
• Will receive immunotherapy during the course of radiotherapy
• Contraindications for biopsy, such as high bleeding risk

Patients proven diagnosis of solid tumors and will have radiotherapy as part of their therapeutic regimens or will undergo surgery in Cancer Hospital of Shantou University Medical College.